Holy Moly - this is an impressive result.
IMU's team are certainly not sitting on their hands.
Conclusions drawn from the study include;
• HER-Vaxx treatment produced robust anti-HER-2-IgG* and IgG1 antibody
responses (p<0.001).
• HER-Vaxx-based vaccination of patients with HER-2 overexpressing
gastric/gastro-esophageal junction cancer (GC) induced anti-HER-2-IgG and IgG1
subclass antibody responses (p<0.001).
• HER-Vaxx induced antibodies correlated with tumour reduction (p=0.001)
• Compared to chemotherapy alone, the vaccination resulted in a statistically
significant overall survival benefit.
• The present data further validate the proof of concept for a first-in-class B-cell
immunotherapy based on HER-2/neu peptides.
Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-18
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.5¢ | $379.9K | 6.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1581916 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 680013 | 6 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |